Medicine and Dentistry
Schistosomiasis
95%
Therapeutic Procedure
84%
Praziquantel
77%
Schistosoma
75%
Chemotherapy
51%
Drug Administration
51%
Antibody
45%
Child
45%
Pediatrics
45%
Infection
34%
Helminth
30%
Cohort Effect
30%
Immune Disorder
30%
Parasite (Microbiology)
30%
School-Aged Child
20%
Parasite Antigen
19%
Phenotype
15%
Drug Efficacy
15%
Health
15%
Adaptive Immunity
15%
Pathology
15%
Lifespan
15%
Vaccine Development
15%
Neglected Tropical Diseases
15%
Ensure
15%
Evaluation Study
15%
Drug
15%
Chemotherapeutic Agent
15%
Schistosoma
15%
Innate Immunity
15%
Monitoring
15%
Public Health
15%
Immunoglobulin
15%
Antibody Response
9%
Immunoglobulin M
9%
Observation
9%
Age
9%
Base
5%
Adjustment
5%
Age Groups
5%
Infant
5%
Anthelmintic
5%
Immunology and Microbiology
Praziquantel
100%
Schistosomiasis
95%
Schistosoma
90%
Health
75%
Monospecific Antibody
45%
Development
36%
Age
35%
Host
34%
Parasite
30%
Parasite Antigen
19%
Morbidity
19%
Intravenous Immunoglobulin
15%
Immunity
15%
Adaptive Immune System
15%
Phenotype
15%
Vaccine Efficacy
15%
Innate Immune System
15%
Genus
15%
Lifespan
15%
Drug Efficacy
15%
Worm
13%
Immunoglobulin M
9%
Isotype
9%
Antibody Response
9%
Infection Rate
6%
Wellbeing
6%
Schistosoma haematobium
6%
Nursing and Health Professions
School-Aged Child
45%
Praziquantel
45%
Schistosomiasis
45%
Morbidity
19%
Child
19%
Age Groups
19%
Infection
12%
Albuminuria
12%
Hematuria
12%
Marker
12%
Proteinuria
12%
Indicator
6%
Preschool Child
6%
Infant
6%
Infection Rate
6%
Odds Ratio
6%
Treatment Outcome
6%